Paula Leferman, APRN
Adult Health · Washington, MINPI 1861804155
Payments from drug & device makers
Across 15 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$139
- Otsuka America Pharmaceutical, Inc.$91
- Teva Pharmaceuticals USA, Inc.$79
- Neurocrine Biosciences, Inc.$27
- Boston Scientific$27
What the payments were for
- Food & beverage$364100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 4 | $139 |
| Otsuka America Pharmaceutical, Inc. | 5 | $91 |
| Teva Pharmaceuticals USA, Inc. | 4 | $79 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Boston Scientific | 1 | $27 |
How this compares
$364 in reported general payments places this provider in the 50th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 417 | $134,909 |
| XareltoRivaroxaban | 107 | $26,522 |
| SantylCollagenase Clostridium Hist. | 21 | $14,414 |
| EntrestoSacubitril/Valsartan | 28 | $10,706 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,186 |
| FarxigaDapagliflozin Propanediol | 23 | $6,703 |
| TradjentaLinagliptin | 22 | $6,038 |
| Atorvastatin Calcium | 355 | $5,924 |
| Midodrine Hcl | 101 | $5,385 |
| Levetiracetam | 100 | $4,387 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $4,101 |
| Ondansetron Hcl | 75 | $4,048 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $3,732 |
| Quetiapine Fumarate | 94 | $3,571 |
| Gabapentin | 228 | $3,237 |
Paid to pharmacies, not to this prescriber.
Other adult health in Washington
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
- Mary KaiserKalamazoo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.